Alimera Sciences Inc - Company Profile
Powered by 
All the data and insights you need on Alimera Sciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Alimera Sciences Inc Strategy Report
- Understand Alimera Sciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Alimera Sciences Inc (Alimera) is a pharmaceutical company that discovers, develops and commercializes prescription ophthalmic pharmaceuticals. The company’s product, Iluvien, is an intravitreal implant of fluocinolone acetonide which is indicated for the treatment of chronic diabetic macular edema (DME) in patients who have been previously treated with corticosteroids and did not show any clinically significant increase in intraocular pressure (IOP). Iluvien is also prescribed for the treatment of recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS); proliferative diabetic retinopathy (NPDR); wet and dry age-related macular degeneration (AMD) and retinal vein occlusion. The company distributes its products in France, Austria, Portugal, the Czech Republic, Denmark, Finland, Germany, Spain, the UK, and others. Alimera is headquartered in Alpharetta, Georgia, the US.
Headquarters
United States of America
Address
Ste 290, 6120 Windward Parkway, Alpharetta, Georgia, 30005
Website
alimerasciences.com
Telephone
1 678 9905740
No of Employees
159
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ALIM (NASD)
Revenue (2022)
$80.8M
49.2%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-11.2%
(2022 vs 2021)
Market Cap*
$190.1M
Net Profit Margin (2022)
XYZ
25.5%
(2022 vs 2021)
* As of and is in US$
Alimera Sciences Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Product: | Iluvein |
| Intravitreal Implant |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In April, the company entered into an agreement with Horus Pharma to expand their relationship beyond France, Belgium, Luxembourg and the Netherlands to increase the commercialization efforts for ILUVIEN for both diabetic macular edema and non-infectious uveitis affecting the posterior segment of the eye in the Nordic countries of Denmark, Finland, Norway and Sweden. |
| 2022 | Contracts/Agreements | In December, the company agreed to an amendment to its existing loan and security agreement with SLR Investment Corp to extend the interest-only period on loan agreement. |
| 2022 | Contracts/Agreements | In September, the company entered into an agreement with the Jaeb Center for Health Research Foundation Inc. |
Competitor Comparison
| Key Parameters | Alimera Sciences Inc | Regeneron Pharmaceuticals Inc | Revance Therapeutics Inc | Titan Pharmaceuticals Inc | RegeneRx Biopharmaceuticals Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Alpharetta | Tarrytown | Nashville | San Francisco | Rockville |
| State/Province | Georgia | New York | Tennessee | California | Maryland |
| No. of Employees | 159 | 13,450 | 534 | 4 | 2 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Richard S. Eiswirth | President; Chief Executive Officer; Director | Executive Board | 2019 | 54 |
| Elliot Maltz | Chief Financial Officer | Senior Management | 2024 | - |
| Jason Werner | Chief Operating Officer | Senior Management | 2023 | - |
| Dave Holland | Senior Vice President - Corporate Communications and Managed Markets; Chief Marketing Officer | Senior Management | 2019 | 59 |
| David Dyer | Chief Retina Specialist | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer